Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tipranks - Tipranks - Thu Apr 16, 1:42AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alcon (ALC), Protagonist Therapeutics (PTGX) and Cannara Biotech (LOVFF) with bullish sentiments.

Claim 30% Off TipRanks

Alcon (ALC)

In a report released yesterday, Jack Reynolds-Clark from RBC Capital maintained a Buy rating on Alcon, with a price target of CHF80.00. The company’s shares closed last Tuesday at $79.94, close to its 52-week low of $77.54.

According to TipRanks.com, Reynolds-Clark is ranked #6078 out of 12179 analysts.

Currently, the analyst consensus on Alcon is a Moderate Buy with an average price target of $97.37, which is a 21.5% upside from current levels. In a report issued on March 30, TipRanks – PerPlexity also upgraded the stock to Buy with a CHF70.00 price target.

See today’s best-performing stocks on TipRanks >>

Protagonist Therapeutics (PTGX)

Wedbush analyst Yun Zhong maintained a Buy rating on Protagonist Therapeutics today and set a price target of $112.00. The company’s shares closed last Tuesday at $104.72.

According to TipRanks.com, Zhong has 0 stars on 0-5 stars ranking scale with an average return of -9.3% and a 39.3% success rate. Zhong covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, CAMP4 Therapeutics Corporation, and MoonLake Immunotherapeutics. ;'>

Protagonist Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $112.82, representing a 15.6% upside. In a report issued on April 3, TipRanks – xAI also upgraded the stock to Buy with a $116.00 price target.

Cannara Biotech (LOVFF)

Atrium Research analyst Nicholas Cortellucci maintained a Buy rating on Cannara Biotech yesterday and set a price target of C$3.00. The company’s shares closed last Tuesday at $1.39.

Cortellucci has an average return of 4.2% when recommending Cannara Biotech. ;'>

According to TipRanks.com, Cortellucci is ranked #11128 out of 12179 analysts.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cannara Biotech with a $2.23 average price target, implying a 64.0% upside from current levels. In a report issued on April 6, Haywood also initiated coverage with a Buy rating on the stock with a C$3.00 price target.

Read More on ALC:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).